Screener
Ultragenyx Pharmaceutical RARE Net Income
Net Income at other companies
Other financials
Where this comes from
Reported directly by Ultragenyx Pharmaceutical in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The source filing: Ultragenyx Pharmaceutical’s 10-Q, filed August 5, 2026. Open the filing →
- Filed
- Aug 4, 2026, 8:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-333233
FAQ
- What is Ultragenyx Pharmaceutical's net income?
- Ultragenyx Pharmaceutical (RARE) reported net income of -$92M in Q2 2026.
- How has Ultragenyx Pharmaceutical's net income changed year-over-year?
- Ultragenyx Pharmaceutical's net income increased by 20.0% year-over-year, from -$115M to -$92M.
- What is the long-term trend for Ultragenyx Pharmaceutical's net income?
- Over 4 years (2021 to 2025), Ultragenyx Pharmaceutical's net income has grown at a 6.1% compound annual growth rate (CAGR), from -$454.03M to -$574.97M.
- What does net income mean?
- The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.
Ask your AI about Ultragenyx Pharmaceutical's net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude